News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
852,583 Results
Type
Article (78875)
Company Profile (729)
Press Release (772962)
Multimedia
Podcasts (189)
Webinars (28)
Section
Business (231706)
Career Advice (3830)
Deals (39645)
Drug Delivery (150)
Drug Development (90602)
Employer Resources (204)
FDA (18257)
Job Trends (17287)
News (394362)
Policy (39370)
Tag
Academia (3009)
Academic (2)
Accelerated approval (34)
Adcomms (36)
Allergies (145)
Alliances (56731)
ALS (180)
Alzheimer's disease (1786)
Antibody-drug conjugate (ADC) (345)
Approvals (18430)
Artificial intelligence (582)
Autoimmune disease (155)
Automation (34)
Bankruptcy (405)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (200)
Biotechnology (452)
Bladder cancer (162)
Brain cancer (65)
Breast cancer (652)
Cancer (4976)
Cardiovascular disease (437)
Career advice (3283)
Career pathing (41)
CAR-T (302)
CDC (59)
Celiac Disease (1)
Cell therapy (808)
Cervical cancer (37)
Clinical research (76365)
Collaboration (1785)
Company closure (5)
Compensation (1147)
Complete response letters (70)
COVID-19 (2990)
CRISPR (98)
C-suite (844)
Cystic fibrosis (154)
Data (6202)
Decentralized trials (2)
Denatured (70)
Depression (149)
Diabetes (528)
Diagnostics (7211)
Digital health (42)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (277)
Drug pricing (221)
Drug shortages (36)
Duchenne muscular dystrophy (238)
Earnings (99452)
Editorial (63)
Employer branding (25)
Employer resources (173)
Events (134603)
Executive appointments (1030)
FDA (21387)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1534)
Gene editing (213)
Generative AI (56)
Gene therapy (659)
GLP-1 (1115)
Government (5407)
Grass and pollen (8)
Guidances (385)
Healthcare (20927)
HIV (59)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (288)
Immuno-oncology (57)
Indications (88)
Infectious disease (3275)
Inflammatory bowel disease (205)
Inflation Reduction Act (17)
Influenza (118)
Intellectual property (243)
Interviews (753)
IPO (17907)
IRA (60)
Job creations (5061)
Job search strategy (2656)
JPM (65)
Kidney cancer (16)
Labor market (91)
Layoffs (655)
Leadership (40)
Legal (10039)
Liver cancer (98)
Longevity (13)
Lung cancer (675)
Lymphoma (375)
Machine learning (44)
Management (66)
Manufacturing (826)
MASH (172)
Medical device (14994)
Medtech (15042)
Mergers & acquisitions (22786)
Metabolic disorders (1379)
Multiple sclerosis (161)
NASH (23)
Neurodegenerative disease (350)
Neuropsychiatric disorders (96)
Neuroscience (3090)
Neurotech (1)
NextGen: Class of 2026 (7661)
Non-profit (5110)
Now hiring (64)
Obesity (668)
Opinion (334)
Ovarian cancer (166)
Pain (204)
Pancreatic cancer (230)
Parkinson's disease (293)
Partnered (37)
Patents (497)
Patient recruitment (470)
Peanut (60)
People (66391)
Pharmaceutical (134)
Pharmacy benefit managers (32)
Phase I (23651)
Phase II (33221)
Phase III (25040)
Pipeline (4884)
Policy (332)
Postmarket research (3373)
Preclinical (10482)
Press Release (72)
Prostate cancer (241)
Psychedelics (53)
Radiopharmaceuticals (297)
Rare diseases (885)
Real estate (7304)
Recruiting (80)
Regulatory (28505)
Reports (66)
Research institute (2718)
Resumes & cover letters (597)
Rett syndrome (27)
RNA editing (20)
RSV (83)
Schizophrenia (158)
Series A (256)
Series B (195)
Service/supplier (28)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (48)
Startups (4281)
State (2)
Stomach cancer (20)
Supply chain (112)
Tariffs (99)
The Weekly (117)
Vaccines (1137)
Venture capital (94)
Weight loss (459)
Women's health (85)
Worklife (21)
Date
Today (101)
Last 7 days (398)
Last 30 days (2204)
Last 365 days (32440)
2026 (2101)
2025 (32676)
2024 (37926)
2023 (42567)
2022 (53929)
2021 (58722)
2020 (57665)
2019 (51315)
2018 (39099)
2017 (36920)
2016 (37939)
2015 (44025)
2014 (39041)
2013 (35321)
2012 (37297)
2011 (37440)
2010 (37360)
Location
Africa (1228)
Alabama (88)
Alaska (7)
Arizona (340)
Arkansas (14)
Asia (50332)
Australia (8640)
California (11446)
Canada (3280)
China (1151)
Colorado (485)
Connecticut (494)
Delaware (341)
Europe (114578)
Florida (1672)
Georgia (368)
Hawaii (4)
Idaho (67)
Illinois (942)
India (65)
Indiana (539)
Iowa (24)
Japan (420)
Kansas (133)
Kentucky (42)
Louisiana (29)
Maine (83)
Maryland (1447)
Massachusetts (8428)
Michigan (349)
Minnesota (660)
Mississippi (6)
Missouri (139)
Montana (35)
Nebraska (29)
Nevada (126)
New Hampshire (85)
New Jersey (3080)
New Mexico (33)
New York (3025)
North Carolina (1594)
North Dakota (10)
Northern California (5467)
Ohio (347)
Oklahoma (22)
Oregon (52)
Pennsylvania (2288)
Puerto Rico (21)
Rhode Island (50)
South America (1595)
South Carolina (64)
South Dakota (1)
Southern California (4422)
Tennessee (174)
Texas (1790)
United States (41247)
Utah (343)
Vermont (1)
Virginia (286)
Washington D.C. (87)
Washington State (955)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
852,583 Results for "merck and co inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
·
2 min read
·
Tristan Manalac
Events
JPM26: Confident Merck Sees Growth Through Keytruda Loss of Exclusivity
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the company is open to deals in the range of “multi tens of billions of dollars.”
January 13, 2026
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
Revolution Knows Its Worth as Merck Backs Off—For Now
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off.
January 26, 2026
·
4 min read
·
Annalee Armstrong
Press Releases
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
October 30, 2025
·
20 min read
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.
January 26, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Merck to Complete Acquisition of Cidara Therapeutics
January 7, 2026
·
6 min read
Earnings
Merck Vaccine Sales Drop as US Declines Strike Another Pharma
While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.
October 30, 2025
·
1 min read
·
Dan Samorodnitsky
Vaccines
As Kennedy Takes Aim at Childhood Vaccines, a History of Merck’s ProQuad
While last week’s recommended changes by CDC advisors to the MMRV vaccine schedule are unlikely to have a tangible effect on Merck’s business, the company said the removal of choice for healthcare providers is “concerning.”
September 23, 2025
·
6 min read
·
Annalee Armstrong
Cancer
Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with immuno-oncology heavyweight Keytruda.
January 20, 2026
·
2 min read
·
Annalee Armstrong
Cardiovascular disease
Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy
Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks.
November 10, 2025
·
2 min read
·
Tristan Manalac
1 of 85,259
Next
